chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pfizer-BioNTech COVID 19 Vaccine EUA.  Reaction started on 8-4-21 in the evening.  Fingers were itchy, progressed to hand and joint pain as the night went on.  Thursday morning  the hand and arm was swollen.  Patient went to Rapid Care facility and noticed hives on legs and abdomen.  The provider administered Dexamethasone and gave prednisone taper to be taken by mouth.  As of evening of 8-5-21, patient was feeling relief of the symptoms.
Felt dizzy and light headed after vaccine. Did not want to take BP due to increasing anxiety. Anxiety before the vaccination. Stayed in store for 30 minutes. I called the patient back at 5:00pm; he stated he was felling fine minus some fatigue.
Severe pain at injection site, Light flashes in left eye, Migraine Headache, Floaters in left eye
Chills, fever, body ache, tiredness and headache. Started at 11 PM yesterday and this have been decreasing in the  past few hours.
She has breast cancer right now; This spontaneous case was reported by a consumer and describes the occurrence of BREAST CANCER (She has breast cancer right now) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BREAST CANCER (She has breast cancer right now) (seriousness criterion medically significant). At the time of the report, BREAST CANCER (She has breast cancer right now) outcome was unknown.            Concomitant medications were not reported . Treatment information was not provided. The patient was due for surgery in 4 to 6 weeks for surgery.  Company comment: This is a spontaneous case concerning an unknown age female patient with no  medical history reported, who experienced the  serious (due to medically important condition) unexpected , according to, event of Breast cancer. Event onset of the event is not provided. The rechallenge was not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning an unknown age female patient with no  medical history reported, who experienced the  serious (due to medically important condition) unexpected , according to, event of Breast cancer. Event onset of the event is not provided. The rechallenge was not applicable. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
This case was reported by a pharmacist via call center representative and described the occurrence of burning sensation in a 63-year-old female patient who received SHINGRIX (batch number 455KD, expiry date 4th May 2021) for prophylaxis. On 14th March 2019, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. In March 2019, 2 days after receiving SHINGRIX, the patient experienced burning sensation. On an unknown date, the outcome of the burning sensation was not recovered/not resolved. It was unknown if the reporter considered the burning sensation to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX in the left deltoid. The patient was having a burning sensation in both her left and right elbows. The reporter was unable to provide additional information. The reporter did not consent to follow up.
fever; chills; fatigue; nausea; sweating; arm hurt; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (sweating), PAIN IN EXTREMITY (arm hurt), PYREXIA (fever), CHILLS (chills) and FATIGUE (fatigue) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 020B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Hypertension. Concomitant products included SPIRONOLACTONE and METOPROLOL for Hypertension.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, the patient experienced PAIN IN EXTREMITY (arm hurt). On 12-Apr-2021, the patient experienced HYPERHIDROSIS (sweating), PYREXIA (fever), CHILLS (chills), FATIGUE (fatigue) and NAUSEA (nausea). On 11-Apr-2021, PAIN IN EXTREMITY (arm hurt) had resolved. At the time of the report, HYPERHIDROSIS (sweating), PYREXIA (fever), CHILLS (chills), FATIGUE (fatigue) and NAUSEA (nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information included Erythromycin.
Pt recv vax on 10/22/98; on 10/23/98 pt exp dec arm movement, pain, swelling
any:    DISORIENTED   Narrative:  Per care not: "Pt was brought in by nurse from parking lot because he was disoriented, dizzy(sudden onset). He saw PCP this morning and received a pneumonia and a flu shot. No itching or any other allergic type symptom. No N/V, afebrile, no CP or SOB. He appears to be confused, but claims is getting better. Hx of Parkinsonism and chronic Atrial Fib" Pt reports that he went to hospital on 9/18/19 from here and they did " all sorts of tests" (CT brain, CXR, labs, ruled out "drugs/alcohol" and they really could not find anything wrong. D/c home w/ wife later that day. Pt reports that he has no memory of  leaving the clinic (after pcp appt) and no memory until "2 days after they sent me home from the hospital". Per pt they only thing they could come up with was "bad combination from the flu shot and the pneumonia vaccine".
This spontaneous report was received from the Medical Assistant (MA) referring to a patient of an unknown age and gender. The information regarding the patient's relevant medical history and concurrent conditions was not provided. On 19-FEB-2015, the patient was vaccinated with improperly stored dose (Oka/Merck) VARIVAX lot # K005427 (expiry date: 15-APR-2016) (start date and dosage not reported). Information regarding the patient's concomitant medications was not provided. No adverse effect reported. The nurse reported a temperature excursion for the (Oka/Merck) VARIVAX. Additionally, the reporter stated that the facility has a data logger but she was not exactly sure what the problem was that caused these excursions. This is one of several reports received from the same reporter. Additional information has been requested. Patient, product and narrative information were updated.
Itching, swelling, redness at injection site; arm pain; diphenhydramine given; history of penicillin allergy.
Case previously recorded as MA2009-4592. Initial case report received from a physician on 17 NOV 2009. A 3-year-old or younger patient was vaccinated with FLUVIRIN 2009/2010 i.m on 13 NOV 2009. No adverse events was reported. Reference no: NA09-008308.
low immunity; received the Hepatitis B series and had negative titers; This serious case was reported by a other health professional via call center representative and described the occurrence of immunodeficiency in an unspecified number of patients who received Hepatitis B vaccine for prophylaxis.   On an unknown date, the patient received Hepatitis B vaccine. On an unknown date, an unknown time after receiving Hepatitis B vaccine, the patient experienced immunodeficiency (Verbatim: low immunity) (serious criteria GSK medically significant) and therapy non-responder (Verbatim: received the Hepatitis B series and had negative titers). The outcome of the immunodeficiency and therapy non-responder were unknown.   It was unknown if the reporter considered the immunodeficiency to be related to Hepatitis B vaccine.     It was unknown if the company considered the immunodeficiency to be related to Hepatitis B vaccine.   Additional Information: GSK Receipt date: 17-JUL-2023 The reporter was a medical assistant. The reporter reported that other patients that received the Hepatitis B series and had negative titers/low immunity where they had to repeat series or a booster. The reporter did not know the brand name/manufacturer of the Hepatitis vaccines received. Their office uses 0.5 ml dose. The reporter consented to follow up. This case was linked with case US2023098115, reported by same reporter.; Sender's Comments:  US-GSK-US2023098115:Same reporter
Sudden numbness in left fourth and fifth fingers, along with outer forearm, associated with ulnar nerve.
In June of 2021 I had dermal filler injected in my nose also known as a liquid rhinoplasty. I was hesitant on getting the vaccine because I was scared of side effects especially with my hyaluronic acid fillers. On December 19 I received my first shot of Pfizer with no reactions my second shot on January 23. 3 weeks later around February 23 my nose was getting inflamed I felt a burning sensation where my filler was placed it hurt so much and it felt like the filler was moving I never had any reaction to this filler for the past 6 months! But now my filler was hurting and burning I contacted my injector and even when she gave me steriods the filler in my nose did not stop hurting and I let her know I think it was triggered by the vaccine. My nose was turning bright red a burning I was rushed to the ER on the 4th of march but had to get my filler dissolved as soon as possible because the pain was getting worse. My injector dissolved all my filler and i felt pain for a few days and dizziness but was able to recover days later. I do believe the vaccine has triggered this reaction.
Patient developed flu-like symptoms the following day including headache, myalgias, fatigue and fever.  This resolved after 24 hrs later.  On Thursday night, he developed severe substernal chest pain that radiated to his back.  Pain improved when he sat up.  He presented to Hospital ED on Friday morning (6/11/21) with continued chest pain and found to have an elevated troponin at 0.561.  Patient was admitted at the time for possible COVID-19 vaccine myo/pericarditis.  His chest pain did resolve with Toradol IV and has been start on full-dose Aspirin.  His troponin has continued to rise however and is now 2.150.
dizziness; irregular heartbeat; aches: legs/shoulders; aches: legs/shoulders; tiredness/weakness when moving about; tiredness/weakness when moving about; Breathing at times tight; This is a spontaneous report received from a contactable consumer (patient) reported for himself. An 82-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number: EW0175, Expiration date was not reported), via an unspecified route of administration in arm left on 13Sep2021 at 14:00 (at the age of 82-year-old) as a dose 1, single for COVID-19 immunization. The patient's medical history included heart decease and high blood pressure from an unspecified date and unknown if ongoing. Known allergies were reported as none. The patient's concomitant medications in two weeks included omeprazole dr, 20 mg and carvedilol 25 mg and other, all were taken for an unspecified indication. The patient did not receive any other vaccines within four weeks. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 16Sep2021 at 12:00 am, three-four days following, the patient experienced dizziness, irregular heartbeat, aches: legs/shoulders, tiredness/weakness when moving about, breathing at times tight but never serious - able to take deep breathes easily. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Treatment was received for the events that included heart monitor by cardiologist. On 16Sep2021, the patient underwent lab tests and procedures which included irregular heartbeat (heart rate), resulted as irregular and BinaxNOW/Abbott (SARS-CoV-2 test), resulted as negative, nasal swab on 28Sep2021. The outcome of the events was unknown.  Follow-up attempts are completed. No further information is expected.
Fever, pain, redness, heat, and rash extending across chest, back, and upper arm, from shoulder to elbow with edema, decreased appetite, general malaise.
Swollen arm about the size of a tennis ball; Fever; Chills; This case was reported by a pharmacist via call center representative and described the occurrence of swelling arm in a 63-year-old female patient who received Herpes zoster (Shingrix) (batch number AP257, expiry date 26th November 2021) for prophylaxis.   On 16th October 2019, the patient received the 1st dose of Shingrix (intramuscular). In October 2019, less than a week after receiving Shingrix, the patient experienced swelling arm, fever and chills. On an unknown date, the outcome of the swelling arm, fever and chills were unknown.   It was unknown if the reporter considered the swelling arm, fever and chills to be related to Shingrix.  Additional case details were reported as follows: The patient received a dose of Shingrix on the left arm. The patient experienced swollen arm about the size of a tennis ball, fever and chills.
On the 7th day after vaccination my arm got a large rash like large Mark.  It is hard, hot, and red.
Eye infection; The initial case was missing the following minimum criteria: as there is no indication that the consumer experienced an event under BNT162B2. Upon receipt of follow-up information on (01Mar2021), this case now contains all required information to be considered valid.  This is a spontaneous report received from a contactable consumer (patient) via a Pfizer-sponsored program . A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: el9266) dose 1 via an unspecified route of administration on 19Feb2021 as a single dose for covid-19 immunisation. The patient medical history included eye infection and concomitant medications were not reported. The patient past drug included ciprofloxacin eye drops. On an unspecified date the patient experienced eye infection. The patient reported that she had 1st dose of vaccine on 19Feb2021 and scheduled on 12Mar2021 for 2nd dose. As per caller a few days after getting the vaccine she ended up with an eye infection, but it's not from the vaccine, its because she used eye make up from a year ago and was prescribed Ciprofloxacin eye drops. She want to make sure the eye drops did not reduce the efficacy of the vaccine. The patient also want to know after 1st dose, was there any protection and after how many days. Hearing a lot of news that people say they get sick after 2nd and it gives 70% protection after 1st dose. Also heard people takes Vitamins D or C before getting the vaccine. Her parents were elderly and thinking if they can get only 1 dose. Also has a 23-year-old daughter autistic has seizures but no seizures when under medication. Outcome of the event was unknown.  No follow-up attempts are possible. No further information is expected.
COVID-19/Treatment of COVID-19; Metallic taste; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19/Treatment of COVID-19) and DYSGEUSIA (Metallic taste) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033F21A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Jansen (Dose Number: 1 Batch/Lot No: 1805018) on 11-Mar-2021. Past adverse reactions to the above products included No adverse event with Jansen. Concurrent medical conditions included Allergy. Concomitant products included ETHINYLESTRADIOL, NORGESTIMATE (TRI-LO-SPRINTEC) and MENTHOL (ROBITUSSIN [MENTHOL]) for an unknown indication.    On 05-Nov-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-May-2022, the patient experienced COVID-19 (COVID-19/Treatment of COVID-19) and DYSGEUSIA (Metallic taste). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) on 25-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19/Treatment of COVID-19) and DYSGEUSIA (Metallic taste) outcome was unknown. Not Provided          Patient was taking any other medications or products within 2 weeks of starting COVID-19 treatment. Device Date was reported as 26-May-2022  Active Drug substance name for Robitussin was reported as Cough suppressant Active Drug substance name for Trilosprintec was reported as Birth control  Company comment:  This spontaneous case concerns a patient of unknown age and gender, with no reported relevant medical history, who experienced, unexpected, non-serious, of COVID-19, approximately 6 months after receiving mRNA-1273 vaccine as a second dose, along with non-serious event of Dysgeusia. Interchange of vaccine products is noted in this case since the patient reported receiving 1 dose of Janssen, approximately 8 months before receiving mRNA-1273 vaccine. The patient was started with Nirmatrelvir-Ritonavir (Paxlovid) dose, duration and frequency were unknown. Clinical course, treatment details and diagnostic tests are not available in this report. The outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a patient of unknown age and gender, with no reported relevant medical history, who experienced, unexpected, non-serious,  of COVID-19, approximately 6 months after receiving mRNA-1273 vaccine as a second dose, along with non-serious event of Dysgeusia. Interchange of vaccine products is noted in this case since the patient reported receiving 1 dose of Janssen, approximately 8 months before receiving mRNA-1273 vaccine. The patient was started with Nirmatrelvir-Ritonavir (Paxlovid) dose, duration and frequency were unknown. Clinical course, treatment details and diagnostic tests are not available in this report. The outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 is not affected by this report.
p/vax pt devel thrombocytopenia purpura & hosp 10/14/99;remained in the ICU as of 10/26/99;
Sevre Tinnitus. Started 10 days post 2nd dose vaccine and has not gone away since. It has changed tone and severity but it mentally crippling. I also had vertigo but that went away a couple months later.
Substantial flu like symptoms. Fever. Chills. Body aches. Minor headache. Stayed in bed all day, 04/09/2021. Felt better and resumed normal life activities the next day, 04/10/2021.
Case received from a healthcare professional on 20Oct05. A 18 year old male pt without relevant medical history had received his first IM injection of Menactra, batch number U1808AA and an IM dose of Fluzone, batch number U1753AA on 18Oct05 and within a few hours later, he developed high fever at 102, shaking and chills. The pt required doctor visit. He received acetaminophen (Tylenol). The fever decreased and the pt was better. However, he was not completely recovered at the time of the report. The pt had no known allergies but experienced high fever after his second dose of hep B vaccine. He did not present with any illness at time of vaccination and did not take medicines. Follow up information received from a health care provider on 28Nov05. There was no illness at the time of vaccination. At the time of this report, the pt had recovered. Further information is not expected.
Nauseated, faint, clammy. Head between legs, gave graham cracker and water. Took blood pressure and pulse.
After about 1 to 2 minutes of receiving vaccine, patient complained of feeling hot & dizzy and collapsed on her way to sit. Had a seizure that lasted about 1 minute and was taken to the ER.
Patient was given an expired vaccination.  He did not have any adverse reaction to it after it was given.  Provider was notified of this afterwards.
I felt a cold coming on before I took the shot the previous day. The shot was given to me because I did not have a fever. Upon returning home I could not stop coughing and thought about going to the ER but did not. I went to the Pharmacy and the Pharmacist recommended taking some DM Cough medicine. I finally contacted my Doctor via tele-services and we discussed the fever, cough and why I was feeling bad.
This spontaneous report as received from a pharmacist refers to an unspecified patients of unknown age and unknown gender. On an unknown date, the unspecified patients were vaccinated with doses of improperly stored ROTATEQ. No adverse effects were reported. This is one of the several reports from the same reporter. Additional information has been requested.
A report has been received from a Health Professional concerning a subject of unknown gender, who had been receiving nasal FLUMIST Quadrivalent. FLUMIST Quadrivalent started on 20-OCT-2014. It was reported that FLUMIST Quadrivalent sprayers were administered reattaching plungers to the sprayers which started on 20-DEC-2014.  The outcome of the event of FLUMIST Quadrivalent sprayers were administered by reattaching plungers to the sprayers is unknown. The report was considered to be non-serious.
2/19/2021 - 8:50AM - severe PAIN IN Back OF NECK AND ACROSS SHOLDERS, SHORTNeSS of BREATH.CHCKED B/P - 85/67. DRANK COLD WATER + LAID on COUCH - subsided in about 10min.  9:00AM - SEVeRe PAIN + MUSCLE CRAMPS, BOTH Legs, fROM knees to toes, couldn't stand up, crying with pain, leaned on walls to get to where husband was, He massaged it with Theraworx ~ 15min, got to wALK then.  Exhausted NOW, Drinking a lot of fluids. 8:00am earlier syMPTOMS = Headache, PAiN IN LefT ARM, SLuggish
Asymptomatic; + Covid pre-procedure test; then s/s covid 2 days later; dx Covid PNA; treated with steroids, Vit C, zinc, neb, O2; remdesivir; prone positioning; Arranged home oxygen Advised to monitor oxygen saturations closely at home
This spontaneous case was reported by a consumer and describes the occurrence of RASH (rash on arm, leg) and PRURITUS (itching) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Mar-2021, the patient experienced RASH (rash on arm, leg) and PRURITUS (itching). At the time of the report, RASH (rash on arm, leg) and PRURITUS (itching) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  No laboratory details were  provided.  No treatment medications were reported.
Breakthrough case after Covid vaccination. Dose #1 2/1/2021 Dose #2 03/05/2021. C/O fever, chills, muscle aches, runny nose, sore throat, loss of taste/smell, headache, fatigue, and cough/onset 9/5/2021
Patient received the booster on 2-2-2022 at 5pm. On 2-3-2022 she began feeling a tingling sensation throughout her fingers and then progressed to her entire body. She felt like she was having an "out of body experience." Vision was affected (the speed of visuospatial recognition  was accelerated, HR 147, b/p 147/90s. Weakness in legs bilaterally.
Breakthrough COVID in fully vaccinated patient requiring hospitalization, patient admitted with weakness and cough, requiring 2L O2
Localized superficial swelling of the skin. No treatment. Symptomatic care was recommended.
Patient complained of shortness of breath after 1st shot.  SOB lasted 2-3 minutes with no rash or swelling.  We are delaying 2nd shot until our Medical Director reviews the chart.
Fever, warms and swollen at site. Could barely raise arm. Fever subsides next day. Swelling pain and redness lasted for about 4 days and started going down on day 5. Did not go to or call doctor.